Wire · operational-macro
FDA approves first ever plasmid DNA-based immunotherapy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 November 2026 · Fusion42 review
The FDA approved Voceryq, the first plasmid DNA-based immunotherapy, to treat recurrent respiratory papillomatosis caused by HPV, marking a breakthrough in DNA-based medicines. This approval validates plasmid DNA therapeutics as a treatment modality, expanding market potential beyond gene therapies and vaccines.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 1 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
You can now build therapies using plasmid DNA as a proven regulatory path exists. Investors and partners will look for DNA-based platform innovators to replicate Inovio's breakthrough.
◆ Coverage
9 sources · first reported 1 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics